April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Effect of DuraSite on the Topical Delivery of Bromfenac to the Ocular Tissues
Author Affiliations & Notes
  • L. M. Bowman
    InSite Vision, Alameda, California
  • E. C. Si
    InSite Vision, Alameda, California
  • K. Hosseini
    InSite Vision, Alameda, California
  • Footnotes
    Commercial Relationships  L.M. Bowman, InSite Vision, E; E.C. Si, InSite Vison, E; K. Hosseini, InSite Vision, E.
  • Footnotes
    Support  InSite Vision
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5298. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. M. Bowman, E. C. Si, K. Hosseini; Effect of DuraSite on the Topical Delivery of Bromfenac to the Ocular Tissues. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5298.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : DuraSite®, a topical polymeric drug delivery system, has been successfully employed to formulate several ocular antibiotics and has shown superior pharmacokinetic profiles. The purpose of this study was to investigate the topical utility of DuraSite for the transport of bromfenac across different ocular tissues and compare this with XibromTM (bromfenac ophthalmic solution, 0.09%).

Methods: : Bromfenac was formulated in DuraSite® at two different concentrations, namely, 0.045% and 0.09%. A single drop of either concentration was applied to the left eye of Dutch Belted rabbits while the same animal received the commercial preparation in the right eye (n=84). The bromfenac concentration in the aqueous humor of each eye was then measured at 0.5, 1, 2, 4, 8, 12, and 24 hours following administration. In a separate study, one drop of either 0.09% experimental or commercial bromfenac preparation was administered to rabbits t.i.d. for 14 days. Two hours after the last dose, various ocular tissues were harvested and assayed for bromfenac content. All analytical procedures used liquid chromatography atmospheric pressure ionization tandem mass spectrometry (LCMS).

Results: : In single dose experiments, the aqueous AUC of 0.045% and 0.09% bromfenac in DuraSite was approximately 2 and 4-fold higher than that of commercial bromfenac ophthalmic solution, 0.09%, respectively. In multi-dose experiments, ocular tissue concentrations of bromfenac in sclera and choroid in the DuraSite group were approximately 3 times as high as the commercial formulation group.

Conclusions: : . Formulations of bromfenac using DuraSite drug delivery system exhibit superior delivery kinetics to various ocular tissues when compared with the commercially available eye drop formulation for both anterior and posterior segments.

Keywords: inflammation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.